Four se­nior FDA lead­ers forged close ties with Bio­gen well ahead of Aduhelm's ap­proval. Now they've left FDA

Two years af­ter the FDA’s con­tro­ver­sial ap­proval of Bio­gen’s Alzheimer’s drug Aduhelm, four of the top agency of­fi­cials who came un­der scruti­ny for their close re­la­tion­ship with the drug­mak­er dur­ing the ap­proval process have left the agency.

Three of those four se­nior of­fi­cials, who man­aged and worked close­ly with the clin­i­cal and biostats re­view­ers as­signed to the Aduhelm ap­pli­ca­tion, have now end­ed up work­ing at drug­mak­ers. The land­ing spot for the fourth — Bil­ly Dunn, for­mer di­rec­tor of the Di­vi­sion of Neu­rol­o­gy Prod­ucts — has yet to be made pub­lic.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.